Previous Close | 0.0343 |
Open | 0.0800 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0800 - 0.0800 |
52 Week Range | 0.0343 - 0.4497 |
Volume | |
Avg. Volume | 822 |
Market Cap | 18.36M |
Beta (5Y Monthly) | 2.53 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2300 |
Earnings Date | Jun 11, 2024 - Jun 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting").
Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
Announced that Al Moghaddam has joined the Company's Board of Directors. Valeo Pharma Inc. shares T.VPH ...